Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables - Net (2022 - 2025)

Historic Receivables - Net for Autolus Therapeutics (AUTL) over the last 4 years, with Q3 2025 value amounting to $32.6 million.

  • Autolus Therapeutics' Receivables - Net changed N/A to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year change of. This contributed to the annual value of $15000.0 for FY2024, which is 8623.85% down from last year.
  • Per Autolus Therapeutics' latest filing, its Receivables - Net stood at $32.6 million for Q3 2025.
  • Autolus Therapeutics' 5-year Receivables - Net high stood at $32.6 million for Q3 2025, and its period low was $15000.0 during Q4 2024.
  • Its 4-year average for Receivables - Net is $10.6 million, with a median of $165000.0 in 2023.
  • Per our database at Business Quant, Autolus Therapeutics' Receivables - Net tumbled by 991.74% in 2023 and then tumbled by 8623.85% in 2024.
  • Over the past 4 years, Autolus Therapeutics' Receivables - Net (Quarter) stood at $121000.0 in 2022, then dropped by 9.92% to $109000.0 in 2023, then crashed by 86.24% to $15000.0 in 2024, then surged by 217260.0% to $32.6 million in 2025.
  • Its Receivables - Net stands at $32.6 million for Q3 2025, versus $26.6 million for Q2 2025 and $14.3 million for Q1 2025.